Q-omics provides the consensus-scored ZNF317 profile across patient tissues and cancer cell-line models. ZNF317 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF317 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF317 RNA expression shows 19,583 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where ZNF317 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF317 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF317 survival associations across molecular data types. ZNF317 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF317 RNA expression–survival associations across cancer types. High ZNF317 expression shows unfavorable associations in ACC and LUSC, but favorable associations in HNSC, KIRC, CHOL and GBM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF317 RNA expression.
This table summarizes ZNF317 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF317. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF317 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, KIRP, LIHC and STAD. The HNSC box plot shows higher ZNF317 RNA expression in tumor versus normal tissue (log2 FC = +0.776, t-test p < 0.001).
This table shows molecular features associated with ZNF317 in patient tissues and cancer cell lines. In patient samples, ZNF317 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF317 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SOFT_TISSUE.
